Outset Medical to Report First Quarter 2023 Financial Results on Wednesday, May 3, 2023

Rhea-AI Summary

Outset Medical, Inc. (NASDAQ: OM) announced plans to release its financial results for Q1 2023 on May 3, 2023, after market close. CEO Leslie Trigg and CFO Nabeel Ahmed will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. The company focuses on revolutionizing dialysis with its Tablo® Hemodialysis System, which simplifies operational processes and enhances patient care. The system integrates water purification and dialysate production, serving as a mobile dialysis clinic. Interested parties can register online for the call and access a live or archived webcast on the Outset Investors page.

Positive

• Launch of the Tablo® Hemodialysis System, improving dialysis cost-effectiveness and patient experience.
• Q1 2023 financial results release expected to provide insight into company performance.

Negative

• None.

SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Wednesday, May 3, 2023. Those interested in listening to the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005053/en/

Jim Mazzola

Vice President, Investor Relations

jmazzola@outsetmedical.com

Brian Johnston

Gilmartin Group

investors@outsetmedical.com

Source: Outset Medical, Inc.

FAQ

When will Outset Medical release its Q1 2023 financial results?

Outset Medical will release its Q1 2023 financial results on May 3, 2023, after market close.

What time is the conference call for Outset Medical's Q1 2023 results?

The conference call will begin at 2:00 PM Pacific Time on May 3, 2023.

How can I listen to the Outset Medical Q1 2023 conference call?

Investors can listen to the conference call by registering online to receive dial-in numbers.

What is the Tablo® Hemodialysis System?

The Tablo® Hemodialysis System is Outset Medical's innovative technology designed to simplify the dialysis process.